Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tumor antigens presented by major histocompatibility complex (MHC) class I molecules and recognized by CD8(+) cytotoxic T lymphocytes (CTLs) may generate an efficient antitumor immune response after appropriate immunization. Antigenic peptides can be used in vivo to induce antitumor or antiviral immunity. The efficiency of naked peptides may be greatly limited by their degradation in the biological fluids. We present a rational, structure-based approach to design structurally modified, peptidase-resistant and biologically active analogues of human tumor antigen MAGE-1.A1. This approach is based on our understanding of the peptide interaction with the MHC and the T cell receptor and its precise degradation pathway. Knowledge of these mechanisms led to the design of a non-natural, minimally modified analogue of MAGE-1.A1, [Aib2, NMe-Ser8]MAGE-1.A1, which was highly peptidase-resistant and bound to MHC and activated MAGE-1.A1-specific anti-melanoma CTLs. Thus, we showed that it is possible to structurally modify peptide epitopes to obtain analogues that are still specifically recognized by CTLs. Such analogues may represent interesting leads for antitumor synthetic vaccines.

Original publication

DOI

10.1074/jbc.274.15.10227

Type

Journal article

Journal

J Biol Chem

Publication Date

09/04/1999

Volume

274

Pages

10227 - 10234

Keywords

Amino Acid Substitution, Antigens, Neoplasm, Cell Line, Chromatography, High Pressure Liquid, Drug Design, HLA-A1 Antigen, Humans, Kinetics, Lymphocyte Activation, Mass Spectrometry, Melanoma, Melanoma-Specific Antigens, Models, Molecular, Molecular Structure, Neoplasm Proteins, Point Mutation, Structure-Activity Relationship, T-Lymphocytes, Cytotoxic